2012 EORTC: Activity of the HSP90 inhibitor AT13387 in ALK-driven tumor models

/in , ,

2012 EORTC: Activity of the HSP90 inhibitor AT13387 in ALK-driven tumor models

2012 ASCO:FIH phase I study-results of HSP90 inhibitor AT13387 in refractory solid tumors

/in , ,

2012 ASCO:FIH phase I study-results of HSP90 inhibitor AT13387 in refractory solid tumors

2012 ASCO: Phase I Study Assessing QDx2 schedule of AT13387 in Advanced Solid Tumors

/in , ,

2012 ASCO: Phase I Study Assessing QDx2 schedule of AT13387 in Advanced Solid Tumors

2012 AACR: AT13387, HSP90 inhibitor effective in vemurafenib-sensitive and -resistant melanoma model

/in , ,

2012 AACR: AT13387, HSP90 inhibitor effective in vemurafenib-sensitive and -resistant melanoma model

2012 Thoracic Symposium: HSP90 Inhibitor AT13387 Effective in Mutant EGFR and ALK-Positive NSCLC

/in , ,

2012 Thoracic Symposium: HSP90 Inhibitor AT13387 Effective in Mutant EGFR and ALK-Positive NSCLC

2011 EORTC: AT13387 Anti-Tumor Activity in imatinib-sensitive and -resistant GIST Models

/in , ,

2011 EORTC: AT13387 Anti-Tumor Activity in imatinib-sensitive and -resistant GIST Models

2010 ASCO: HSP90 Inhibitor in Refractory Solid Tumors: Phase I Study of AT13387

/in , ,

2010 ASCO: HSP90 Inhibitor in Refractory Solid Tumors: Phase I Study of AT13387

2007 Gordon: Fragment Based Drug Design of AT13387 A Novel and Efficacious HSP90 Inhibitor

/in , ,

2007 Gordon: Fragment Based Drug Design of AT13387 A Novel and Efficacious HSP90 Inhibitor